Ironwood Pharmaceuticals, Inc. (IRWD) Stock Forecast
IRWD analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.75 / 5 from 4 analysts
- Price target
- $6.10 average of analyst targets
- Upside to target
- +74.3% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $0.30
- 52-week range
- $1.50 – $5.39
IRWD analyst ratings
4 analystsNumber of analysts at each rating.
IRWD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IRWD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.31 | $0.30 | $0.32 | $0.24 | +29.2% | 2 |
| Current fiscal year (2026) | $1.21 | $1.20 | $1.22 | $0.25 | +384.0% | 2 |
| Next fiscal year (2027) | $1.50 | $1.25 | $1.82 | $1.21 | +24.0% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IRWD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $121.6M | $120.4M | $122.3M | −0.4% | 3 |
| Current fiscal year (2026) | $471.4M | $466.6M | $475.5M | +59.2% | 3 |
| Next fiscal year (2027) | $494.1M | $470.3M | $508.4M | +4.8% | 4 |
IRWD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IRWD revenue: reported and forecast
IRWD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.29 | $0.29 | $0.31 | $0.31 | $0.31 | +6.9% | 1 up · 0 down |
| Current fiscal year (2026) | $1.09 | $1.09 | $1.21 | $1.21 | $1.21 | +11.0% | 1 up · 0 down |
| Next fiscal year (2027) | $1.44 | $1.44 | $1.50 | $1.50 | $1.50 | +4.2% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IRWD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IRWD beat in 4 of 12.
What analysts expect from IRWD
4 analysts cover Ironwood Pharmaceuticals; their consensus rating is buy (3.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.10, 74.3% above the latest close of $3.50. Analysts expect earnings of $1.21 per share for 2026, +384.0% from a year earlier. For 2027 the average estimate is $1.50 per share on revenue of $494.1 million. Ironwood Pharmaceuticals beat the EPS estimate in 4 of the last 12 quarters.
Related: IRWD income statement, IRWD key metrics, IRWD chart. See the IRWD stock overview for the latest quote and news.
IRWD forecast FAQ
What is Ironwood Pharmaceuticals's price target?
The average analyst price target for Ironwood Pharmaceuticals is $6.10, 74.3% above the latest close of $3.50.
Is Ironwood Pharmaceuticals a buy, hold or sell?
Of 4 analysts covering Ironwood Pharmaceuticals, 1 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ironwood Pharmaceuticals's EPS forecast?
Analysts forecast $1.21 per share for 2026 (range $1.20 to $1.22); for 2027 the estimate is $1.50.
What is Ironwood Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $471.4 million, growth of 59.2%; for 2027 it is $494.1 million.
When does Ironwood Pharmaceuticals report earnings?
Ironwood Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 before the market opens; the EPS estimate is $0.30.
Does Ironwood Pharmaceuticals usually beat earnings estimates?
Ironwood Pharmaceuticals reported EPS at or above the analyst estimate in 4 of the last 12 quarters.